(NASDAQ: ARVN) Arvinas's forecast annual revenue growth rate of -16.13% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.67%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.46%.
Arvinas's revenue in 2026 is $262,600,000.On average, 20 Wall Street analysts forecast ARVN's revenue for 2026 to be $5,702,378,727, with the lowest ARVN revenue forecast at $1,040,517,499, and the highest ARVN revenue forecast at $11,537,924,249. On average, 16 Wall Street analysts forecast ARVN's revenue for 2027 to be $5,096,476,202, with the lowest ARVN revenue forecast at $1,943,135,089, and the highest ARVN revenue forecast at $10,000,301,881.
In 2028, ARVN is forecast to generate $11,550,716,448 in revenue, with the lowest revenue forecast at $2,946,043,522 and the highest revenue forecast at $36,930,440,058.